Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
EU Approval:
The European Commission has granted unconditional approval for Novo Holdings' acquisition of Catalent, a global contract development and manufacturing organization13.
Transaction Value:
The acquisition is valued at $16.5 billion3.
Expected Closure:
The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions and receipt of required regulatory approvals12.
Post-Acquisition Plans:
Novo Holdings plans to divest three of Catalent’s global sites to Novo Nordisk post-acquisition. These sites are located in Bloomington, Indiana; Brussels, Belgium; and Anagni, Italy24.
Strategic Benefits:
The acquisition will provide Catalent with access to Novo Holdings' significant resources, enabling it to accelerate its strategy and enhance value for stakeholders and patients25.
Regulatory Approvals:
The acquisition has been approved by authorities in multiple jurisdictions and is pending additional regulatory consents in other regions45.
Sources:
1. https://www.catalent.com/catalent-news/catalent-and-novo-holdings-receive-european-commission-unconditional-approval-for-pending-transaction/
2. https://transaction.catalent.com
3. https://www.investing.com/news/stock-market-news/novo-holdings-165-billion-catalent-buy-wins-eu-antitrust-approval-3759717
4. https://www.globenewswire.com/news-release/2024/12/06/2993201/0/en/The-European-Commission-approves-the-acquisition-of-Catalent-by-Novo-Holdings-and-the-related-acquisition-by-Novo-Nordisk-of-three-manufacturing-sites-from-Novo-Holdings.html
5. https://www.pharmaceutical-technology.com/news/novo-acquisition-catalent-ec/